Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - INSMED Inc | a13-22301_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 15, 2013
INSMED INCORPORATED
(Exact name of registrant as specified in its charter)
|
Virginia |
|
0-30739 |
|
54-1972729 |
|
(State or other jurisdiction of Incorporation) |
|
(Commission File N umber) |
|
(I.R.S. Employer Identification No.) |
|
9 Deer Park Drive, Suite C, Monmouth Junction, New Jersey |
|
08852 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (732) 997-4600
|
Not Applicable |
|
(Former name or former address, if changed from last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On October 15, 2013, Insmed Incorporated (the “Company”) issued a press release announcing the completion of patient enrollment for the Company’s phase 2 clinical study of ARIKACE® (liposomal amikacin for inhalation) for patients with recalcitrant nontuberculous mycobacterial (NTM) lung disease in the United States and Canada. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release dated October 15, 2013 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 15, 2013
|
|
INSMED INCORPORATED | |
|
|
|
|
|
|
By: |
/s/ Christine Pellizzari |
|
|
Name: |
Christine Pellizzari |
|
|
Title: |
General Counsel and Corporate Secretary |